Lung Cancer Trials Ask AI to find trials
Enrolling By InvitationNot applicableNCT04945317
Official study title

ROSE for Improved Molecular Marker Testing Via EBUS

Study summary

This research study is being done to compare two ways to conduct bronchoscopic biopsy of lymph nodes and other structures in the chest (i.e. the presence or absence of an on-site cytotechnologist performing a limited microscopic evaluation to provide non-binding feedback on specimen adequacy in real time during the procedure).

Ask AI to explain this study
Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedROSE (presence of cytotech) & liquid prep and NO-ROSE (absence of cytotech) & liquid prep

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 17, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Enrolling By Invitation

Participation is limited to people invited by the study team.

What kind of study?Not applicable

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Johns Hopkins University

Study sponsor

01
Study overview

What this study is about

Purpose
Other
Study type
Interventional
Phase
Not applicable
Sponsor
Johns Hopkins University
Interventions being studied
Other: ROSE (presence of cytotech) & liquid prep; Other: NO-ROSE (absence of cytotech) & liquid prep; Other: ROSE (presence of cytotech) & tissue clot sample; Other: NO-ROSE (absence of cytotech) & tissue clot sample
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Inpatients or outpatients \>18 years old
  • Capable of informed consent
  • Known or suspected non-small cell lung cancer (NSCLC)
  • Referred to the interventional pulmonary team at Johns Hopkins Hospital (JHH), Johns Hopkins Bayview Medical Center (JHBMC), or other participating sites for tissue sampling of a hilar/mediastinal lymph node or another lesion accessible by convex-probe (CP) EBUS
Reasons someone may not be able to joinExclusion criteria
  • Refuse participation
  • Standard contraindications to EBUS and bronchoscopy in general: bleeding disorders, antiplatelet or anticoagulant usage, high fraction of inspired oxygen (FiO2) requirement, and clinical instability
  • Pregnant women
  • Cytotechnologist not available at the time of screening, enrollment, or randomization

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Northwestern MedicineChicago, Illinois
  • Johns Hopkins Bayview Medical CenterBaltimore, Maryland
  • Johns Hopkins HospitalBaltimore, Maryland
  • The Medical University of South Carolina (MUSC)Charleston, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 17, 2025. Always confirm current availability with the study team.

View original record ↗